Technology | Leads Implantable Devices | May 09, 2017

Biotronik Receives FDA Approval for Sentus ProMRI Quadripolar Left Ventricular Lead

Quadripolar lead with MR conditional CRT-D ensures heart failure patients have access to MRI scans

Biotronik Receives FDA Approval for Sentus ProMRI Quadripolar Left Ventricular Lead

May 9, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval and the launch of Sentus ProMRI, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes Biotronik's second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI.

Sentus ProMRI is approved for use with heart failure devices based on data collected during the QP ExCELs study. The study, which included 53 sites in the United States, demonstrated Sentus ProMRI QP's performance. Key data points included:

  • Complication-free rate of 97.1 percent at six months;
  • Lead dislodgement rate of 1.43 percent; and
  • Achievement of permanent pacing vector pacing threshold lower than 2.5 V for 93.4 percent of subjects at three months.

Sentus ProMRI is a quadripolar coronary sinus left ventricular (LV) lead with an isodiametric design that marries co-radial wire insulation technology and polyurethane coating for maximum flexibility and reduced friction. The lead's four electrodes feature Biotronik’s fractal iridium coating to maximize performance.

"With the array of leads available today, every patient should be implanted with an MR conditional device," said Venkat R. Iyer, M.D., electrophysiologist at Bayview Physicians Group in Norfolk, Va. "Our patients deserve nothing less than the best possible care. With MR [magnetic resonance] conditional solutions, we can help ensure this continues throughout the patient care journey."

Sentus ProMRI completes the ProMRI quadripolar system when used with Biotronik's Inventra HF-T QP cardiac resynchronization therapy defibrillator (CRT-D). This makes it the only MR conditional heart failure solution available in the United States that delivers ultra-high energy (42J) therapy on the first and every shock, according to the company. This system offers Closed Loop Stimulation (CLS) — Biotronik’s physiologic rate-adaptive algorithm that automatically optimizes to each patient's needs based on real-time metabolic demand. It also features Biotronik Home Monitoring, which has shown a 50 percent reduction in mortality1 in patients with heart failure, as proven in the IN-TIME study.

For more information: www.biotronik.com

 

Reference
1. Hindricks G, et al. The Lancet. 2014, 384 (9943).

Related Content

His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init